
European Medicines Agency Validates Marketing Authorization Application for Tisotumab Vedotin in Treating Recurrent or Metastatic Cervical Cancer
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE PFE) have announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for tisotumab vedotin, an antibody-drug conjugate…












